Although EZH2 was thought to be an oncogene, deletion of EZH2 in mouse and human group 3 cells by CRISPR/cas9 gene editing approaches have resulted in loss of PRC2 complex, accelerating tumor growth [129]. The gene discussed is EZH2; the disease is neoplasm.